Suven Life Sciences to Present Pipeline Progress at CTAD 2026
Suven Life Sciences Ltd 路 Press Release 路 16 Nov 2026, 5:51 pm
Suven Life Sciences to Present Pipeline Progress at CTAD 2026 Suven Life Sciences will present clinical updates on Masupirdine (SUVN-502) and Tenaclidine (SUVN-I6107) at the CTAD conference from 16th to 19th Nov'26 in Boston. Patient enrollment is complete for Masupirdine鈥檚 global Phase-3 study targeting agitation in Alzheimer鈥檚 dementia, with no major safety concerns reported and topline results anticipated in Q2'27. Additionally, Phase-1 SAD and MAD data for Tenaclidine demonstrated positive safety, tolerability, and pharmacokinetic profiles in healthy subjects, supporting its planned advancement into patient-level clinical studies for cognitive disorders.
Original exchange filing (PDF)
More announcements from Suven Life Sciences Ltd
- Please find enclosed the News Release of our Company 路 16 Nov 2026
- Please find enclosed News Release of our Company 路 12 Nov 2026
- Monitoring Agency Report for the quarter ended 30th September, 2026 路 06 Nov 2026
- Un-audited financial results for the quarter and half year ended 30th September 2026 路 05 Nov 2026
- Un-audited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30th September, 2026 路 05 Nov 2026
- Suven Life Sciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 05 Nov 2026
- SUVEN LIFE SCIENCES LIMITED has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . 路 05 Nov 2026
- SUVEN LIFE SCIENCES LIMITED has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . 路 05 Nov 2026
